Mapi Pharma Ltd. announced that it has entered into a security purchase agreement for private placement of maximum of 92,590,000 shares at not more than $10.80 per share for gross proceeds of $10,000,000 on January 3, 2016. The transaction will include participation from new investor Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.39 CNY | -1.05% | +0.39% | -18.32% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.32% | 1.24B | |
+54.07% | 816B | |
+38.59% | 634B | |
-7.05% | 351B | |
+15.44% | 323B | |
+5.72% | 293B | |
+13.40% | 238B | |
+0.61% | 222B | |
+13.24% | 218B | |
+7.42% | 167B |
- Stock Market
- Equities
- 002020 Stock
- News Zhejiang Jingxin Pharmaceutical Co., Ltd.
- Mapi Pharma Ltd. announced that it expects to receive $10 million in funding from Zhejiang Jingxin Pharmaceutical Co., Ltd..